Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

9 of 9+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, United States· US$2,729,322 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, United States· US$514,864 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, United States· US$518,589 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, United States· US$130,125 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, United States· US$613,866 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 74 running projects, newest first. Listed amounts together: US$30.6m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Recovering anaerobic bacterial genomes in saliva, tumour and blood whole genome sequencing data from patients with prostate cancer.

  NPJ Biofilms Microbiomes, Oct 2026

• The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.

  Nat Commun, Oct 2026

• Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities.

  PLoS One, Oct 2026

• Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.

  Nat Commun, Sept 2026

• Shallow Whole-Genome Sequencing to Assess Genomic Instability and Predict Treatment Response in Metastatic Castration-Resistant Prostate Cancer.

  JCO Precis Oncol, Jul 2026

• Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

  Nat Commun, Jun 2026

• cyberDMR: accurate and robust identification of differentially methylated regions from WGS-derived methylomes.

  BMC Biol, May 2026

• Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data.

  JCO Clin Cancer Inform, Jan 2026

• Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer.

  Nat Commun, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.